90 related articles for article (PubMed ID: 8712712)
1. The activity of N-(hydroxymethyl) melamines in fresh human ovarian tumour cells and xenografts.
Coley HM; Jarman M; Jones M; Sargent JM; Kubota T; Lee NC; Goddard PM; Elgie AW; Williamson C; Taylor CG; Judson IR
Anticancer Res; 1996; 16(4A):1851-5. PubMed ID: 8712712
[TBL] [Abstract][Full Text] [Related]
2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol.
Coley HM; Jarman M; Brooks N; Kubota T; Goddard PM; Jones M; Lee N; Owens MD; Halbert GW; Judson IR
Int J Cancer; 1996 Nov; 68(3):356-63. PubMed ID: 8903478
[TBL] [Abstract][Full Text] [Related]
4. Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines.
Coley HM; Jarman M; Brooks N; Thornton TJ; Judson IR
Eur J Cancer; 1994; 30A(12):1827-36. PubMed ID: 7880614
[TBL] [Abstract][Full Text] [Related]
5. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of hexamethylmelamine on human tumor xenografts serially transplanted in nude mice.
Kubota T; Tanino H; Watanabe M; Kitajima M
Anticancer Res; 1994; 14(6B):2521-4. PubMed ID: 7872676
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
[TBL] [Abstract][Full Text] [Related]
8. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
9. N-(Hydroxymethyl) melamines.
Coley HM
Gen Pharmacol; 1997 Feb; 28(2):177-82. PubMed ID: 9013191
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
12. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivatives.
Moebus VJ; Stein R; Kieback DG; Runnebaum IB; Sass G; Kreienberg R
Anticancer Res; 1997; 17(2A):815-21. PubMed ID: 9137413
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
15. In vitro chemosensitivity testing of human tumours by collagen gel droplet culture and image analysis.
Tanigawa N; Kitaoka A; Yamakawa M; Tanisaka K; Kobayashi H
Anticancer Res; 1996; 16(4A):1925-30. PubMed ID: 8712722
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human breast cancer metastasis in nude mice by synthetic glycoamines.
Glinsky GV; Price JE; Glinsky VV; Mossine VV; Kiriakova G; Metcalf JB
Cancer Res; 1996 Dec; 56(23):5319-24. PubMed ID: 8968076
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo pharmacological characterisation of the antitumour properties of pyrido[1',2':1,2]imidazo[4,5-h]quinazoline.
Dupuy M; Blache Y; Bailly C; Poujol S; Chapat JP; Pinguet F
Anticancer Res; 2002; 22(6A):3365-71. PubMed ID: 12530088
[TBL] [Abstract][Full Text] [Related]
20. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
